Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial

Hiten D. Patel, Farzana A. Faisal, Bruce Trock, Gregory A. Joice, Zeyad R. Schwen, Phillip Martin Pierorazio, Michael Johnson, Trinity Bivalacqua, Misop Han, Michael Gorin, H Ballentine Carter, Alan Partin, Christian P. Pavlovich, Mohamad E. Allaf

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

In the Prevention of Venous Thromboembolism Following Radical Prostatectomy (PREVENTER) randomized trial, pharmacologic prophylaxis did not reduce the rate of symptomatic (relative risk [RR] 0.40 [95% confidence interval {CI} 0.08–2.03], p = 0.267) or overall (RR 0.97 [95% CI 0.25–3.81], p = 0.967) venous thromboembolism significantly. There was no increase in adverse events including symptomatic lymphoceles or bleeding.

Original languageEnglish (US)
Pages (from-to)360-368
Number of pages9
JournalEuropean Urology
Volume78
Issue number3
DOIs
StatePublished - Sep 2020

Keywords

  • Clinical trial
  • Evidence-based medicine
  • Quality improvement
  • Radical prostatectomy
  • Surgery
  • Venous thromboembolism

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial'. Together they form a unique fingerprint.

Cite this